These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 27438183)

  • 41. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy.
    Specchio LM; Gambardella A; Giallonardo AT; Michelucci R; Specchio N; Boero G; La Neve A
    Epilepsy Res; 2006 Sep; 71(1):32-9. PubMed ID: 16814521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical expression and EEG features of patients with juvenile myoclonic epilepsy (JME) from North India.
    Mehndiratta MM; Aggarwal P
    Seizure; 2002 Oct; 11(7):431-6. PubMed ID: 12237068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term follow-up with therapeutic drug monitoring of antiepileptic drugs in patients with juvenile myoclonic epilepsy.
    Johannessen Landmark C; Fløgstad I; Baftiu A; Syvertsen M; Enger U; Koht J; Johannessen SI
    Epilepsy Res; 2019 Sep; 155():106148. PubMed ID: 31195184
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of valproate on the sleep microstructure of juvenile myoclonic epilepsy patients - a cross-sectional CAP based study.
    Nayak CS; Sinha S; Nagappa M; Kandavel T; Taly AB
    Sleep Med; 2016 Jan; 17():129-33. PubMed ID: 26847987
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy.
    Rocamora R; Wagner K; Schulze-Bonhage A
    Seizure; 2006 Sep; 15(6):428-33. PubMed ID: 16837220
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Juvenile myoclonic epilepsy: a 5-year prospective study.
    Panayiotopoulos CP; Obeid T; Tahan AR
    Epilepsia; 1994; 35(2):285-96. PubMed ID: 8156946
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors associated with lack of response to valproic acid monotherapy in juvenile myoclonic epilepsy.
    Jayalakshmi S; Vooturi S; Bana AK; Sailaja S; Somayajula S; Mohandas S
    Seizure; 2014 Aug; 23(7):527-32. PubMed ID: 24794160
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center.
    Cação G; Parra J; Mannan S; Sisodiya SM; Sander JW
    Epilepsy Behav; 2018 May; 82():81-86. PubMed ID: 29602081
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors for long-term seizure outcome in juvenile myoclonic epilepsy: 25-63 years of follow-up.
    Geithner J; Schneider F; Wang Z; Berneiser J; Herzer R; Kessler C; Runge U
    Epilepsia; 2012 Aug; 53(8):1379-86. PubMed ID: 22686598
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors of Seizure Recurrence in Women With Idiopathic Generalized Epilepsy Who Switch From Valproate to Another Medication.
    Cerulli Irelli E; Cocchi E; Morano A; Gesche J; Caraballo RH; Lattanzi S; Strigaro G; Rosati E; Catania C; Ferlazzo E; Casciato S; Di Gennaro G; Pizzanelli C; Giuliano L; Viola V; Mostacci B; Pignatta P; Fortunato F; Pulitano P; Panzini C; Gambardella A; Atalar AÇ; Labate A; Operto FF; Giallonardo AT; Baykan BB; Beier CP; Di Bonaventura C;
    Neurology; 2024 May; 102(9):e209222. PubMed ID: 38569127
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Encephalopathy induced by levetiracetam added to valproate.
    Bauer J
    Acta Neurol Scand; 2008 May; 117(5):374-6. PubMed ID: 18081909
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
    Mink S; Muroi C; Seule M; Bjeljac M; Keller E
    Clin Neurol Neurosurg; 2011 Oct; 113(8):644-8. PubMed ID: 21703756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes.
    Di Bonaventura C; Fattouch J; Mari F; Egeo G; Vaudano AE; Prencipe M; Manfredi M; Giallonardo AT
    Epileptic Disord; 2005 Sep; 7(3):231-5. PubMed ID: 16162433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of levetiracetam for reducing rolandic discharges in comparison with carbamazepine and valproate sodium in rolandic epilepsy.
    Kanemura H; Sano F; Ohyama T; Aihara M
    Seizure; 2018 Nov; 62():79-83. PubMed ID: 30308427
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and neuropsychological considerations in a case of unrecognized myoclonic epileptic jerks dramatically controlled by levetiracetam.
    Gentile V; Brunetto D; Leo I; Bonetti S; Verrotti A; Franzoni E
    Neuropediatrics; 2010 Dec; 41(6):270-2. PubMed ID: 21445819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Behavioral effects and somnolence due to levetiracetam versus oxcarbazepine - a retrospective comparison study of North Indian patients with refractory epilepsy.
    Shukla G; Gupta A; Agarwal P; Poornima S
    Epilepsy Behav; 2016 Nov; 64(Pt A):216-218. PubMed ID: 27756024
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence.
    Cavitt J; Privitera M
    Arch Neurol; 2004 Oct; 61(10):1604-7. PubMed ID: 15477517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study.
    Delanty N; Jones J; Tonner F
    Epilepsia; 2012 Jan; 53(1):111-9. PubMed ID: 22050371
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and tolerability of anti-epileptic drugs-an internet study.
    Wieshmann UC; Baker G
    Acta Neurol Scand; 2017 May; 135(5):533-539. PubMed ID: 27757951
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effects of levetiracetam, carbamazepine, and sodium valproate on P100 and P300 in epileptic patients.
    Tumay Y; Altun Y; Ekmekci K; Ozkul Y
    Clin Neuropharmacol; 2013; 36(2):55-8. PubMed ID: 23503548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.